Abeona Therapeutics (NASDAQ:ABEO) released its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05), Bloomberg Earnings reports. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.24 million. The company’s revenue was down 16.0% on a year-over-year basis.
Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at $15.35 on Friday. Abeona Therapeutics has a 52-week low of $4.55 and a 52-week high of $22.75. The company has a market capitalization of $718.00, a PE ratio of -23.26 and a beta of 1.30.
A number of research firms have commented on ABEO. ValuEngine upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Abeona Therapeutics in a research report on Thursday, February 1st. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Wednesday, November 22nd. Maxim Group set a $35.00 target price on Abeona Therapeutics and gave the company a “buy” rating in a research report on Monday, November 20th. Finally, BidaskClub upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $27.11.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.